High-precision radiation therapy with integrated biological imaging and tumor monitoring: Evolution of the Munich concept and future research options

Strahlentherapie und Onkologie

Volumn 182, Issue 7, 2006, Pages 361-368

  Grosu, Anca L ^a   Molls, Michael ^a   Zimmermann, Frank B ^a   Geinitz, Hans ^a   Nüsslin, Fridtjof ^a   Schwaiger, Markus ^a   Nieder, Carsten ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biological imaging; Positron emission tomography; Radiation treatment planning; Radiotherapy; Treatment monitoring

Indexed keywords

ACCURACY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; DOSIMETRY; HUMAN; IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

ANIMALS; CLINICAL TRIALS; DOSE FRACTIONATION; GERMANY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 33745795974     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1504-1     Document Type: Review

References (80)

1. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004;59:1295-300.
2. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-72.
3. Bignardi M, Antognoni P, Sanguineti G, et al. Hyperfractionated radiotherapy for T2NO glottic carcinoma: a retrospective analysis at 10 years follow-up in a series of 60 consecutive patients. Tumori 2004;90:317-23.
4. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41.
5. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:349-53.
6. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125-35.
7. Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528-35.
8. Chang AT, Leung SF, Ngan RK. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-9.
9. Chen X, Sievers E, Hou Y, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005,7:271-9.
10. Chernov MF, Hayashi M, Izawa M, et al. Early metabolic changes in metastatic brain tumors after gamma knife radiosurgery: 1H-MRS study. Brain Tumor Pathol 2004;21:63-7.
11. De Boer JR, Pruim J, Albers FW, et al. Prediction of survival and therapy outcome with HC-tyrosine PET in patients with laryngeal carcinoma. J Nucl Med 2004;45:2052-7.
12. Deniaud-Alexandre E, Touboul E, Tiret E, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003;56:1259-73.
13. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
14. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. J Clin Oncol 2004;22:872-80.
15. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60.
16. Feldmann HJ, Molls M, Vaupel P. Blood flow and oxygenation status of human tumors. Strahlenther Onkol 1999;175:1-9.
17. Feldmann HJ, Sievers K, Füller J, et al. Evaluation of tumor blood perfusion by dynamic MRI and CT in patients undergoing thermoradiotherapy. Eur J Radiol 1993;16:224-9.
18. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys 2005;62:70-5.
19. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
20. 18F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-22.
21. Garden AS, Forster K, Wong PF, et al. Results of radiotherapy for T2NO glottic carcinoma: does the "2" stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003;55:322-8.
22. Gerard JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998;46:249-56.
23. Groen HJ, van der Leest AH, Fokkema E, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small cell lung cancer: a multicenter phase III study. Ann Oncol 2004;15:427-32.
24. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18- fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-95.
25. Grosu AL, Feldmann HJ, Dick S, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int Radiat Oncol Biol Phys 2003;54:842-4.
26. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483-99.
27. 18F-FAZA-PET to radiation treatment planning in head and neck cancer. Strahlenther Onkol 2005;181:Sondernr 1:23.abstract.
28. Grosu AL, Weber WA, Feldmann HJ, et al. First experience with I-123-alpha-methyl-tyrosine SPECT in 3-D radiation treatment planning of brain gliomas. Int Radiat Oncol Biol Phys 2000;47:517-26.
29. Grosu AL, Weber WA, Franz M, et al. Re-irradiation of recurrent high grade gliomas using amino-acids-PET(SPECT)/CT/MRI image fusion to determine gross tumor volume forstereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:511-9.
30. Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high grade gliomas before radiation therapy. Int J Radiat Oncol Biol Phys 2005;63:64-74.
31. Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004;199:1-7.
32. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alpha v beta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
33. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003;9:5666-74.
34. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.
35. Hilbig H, Hanne R, Kneschaurek P, et al. Entwicklung eines inversen Bestrahlungsplanungssystems mit linearer Optimierung. Med Physik 2002;12:89-96.
36. Ishimori T, Saga T, Nagata T, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004;18:669-74.
37. Jones AS, Fish B, Fenton JE, et al. The treatment of early laryngeal cancers (T1-T2 NO): surgery or irradiation? Head Neck 2004;26:127-35.
38. Keen HG, Dekker BA, Disley L, et al. Imaging apoptosis in vivo using 1241-annexin V and PET. Nucl Med Biol 2005;32:395-402.
39. Kim S, Chung JK, Im SH, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52-9.
40. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004;59:1424-31.
41. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
42. Lyng H, Vorren AO, Sundfor K, et al. Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy. Int J Cancer 2001;96:182-90.
43. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-95.
44. Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005;61:809-16.
45. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005;102:5524-9.
46. Molls M, Vaupel P. Blood perfusion and microenvironment of human tumors - implications for clinical radiooncology. Berlin-Heidelberg-New York: Springer, 2000.
47. Nieder C, Grosu AL, Mehta MP, et al. Treatment of malignant gliomas in adults: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother 2004;4:691-703.
48. Nieder C, Petersen S, Petersen C, et al. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 2000;26:67-73.
49. Nieder C, Schlegel J, Andratschke N, et al. The role of growth factors in central nervous system tumours. Anticancer Res 2003;23:1681-6.
50. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
51. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiotherapy. An international multicenter study. Radiother Oncol 2005;77:18-24.
52. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48:43-52.
53. Ohashi T, Takeda A, Shigematsu N, et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 2005;62:1003-8.
54. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer 2004;101:1623-31.
55. Ortholan C, Ramaioli A, Peiffert D, et al. Anal canal carcinoma: early-stage tumors < or = 10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:479-85.
56. Papillon J. Present status of radiation therapy in the conservative management of rectal cancer. Radiother Oncol 1990;17:275-83.
57. Peller M, Weissfloch L, Stehling MK, et al. Oxygen induced MR-signal changes in murine tumors. Magn Reson Imaging 1998;16:799-809.
58. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
59. Rietzel E, Chen GT, Choi NC, et al. Four-dimensional image-based treatment planning: target volume segmentation and dose calculation in the presence of respiratory motion. Int J Radiat Oncol Biol Phys 2005;61:1535-50.
60. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
61. Rofstad EK, Sundfor K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83:354-9.
62. Röper B, Nüse N, Pigorsch S, et al. Sonographic maximal malignancy criteria count (MMCC) of lymph nodes predicts survival in H&N cancer stage IVA - mature data on a new prognostic factor. Strahlenther Onkol 2005;181: Sondernr 1:23.abstract.
63. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small cell lung cancer. J Clin Oncol 2005;23:1136-43.
64. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-9.
65. Schäfer M, Münter M, Sterzing F, et al. Measurements of characeristics of time pattern in dose delivery in step-and-shoot IMRT. Strahlenther Onkol 2005;181:587-94.
66. Selch MT, Ahn E, Laskari A, et al. Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 2004;59:101-11.
67. Sperti C, Pasquali C, Chierichetti F, et al. 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953-9.
68. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-54.
69. Stadler P, Feldmann HJ, Creighton C, et al. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol 1998;48:157-64.
70. Stadler P, Feldmann HJ, Creighton C, et al. Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck. Int J Biol Markers 2000;15:235-6.
71. Swisher SG, Erasmus J, Maish M, et al. 2-fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-85.
72. Van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
73. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24.
74. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 2003;57:1297-303.
75. Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-(123I)-iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144-50.
76. Weber WA, Dietlein M, Hellwig D, et al. PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin 2003;42:135-44.
77. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.
78. Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
79. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005;48:107-14.
80. Zips D, Adam M, Flentje M, et al. Impact of hypoxia and the metabolic microenvironment on radiotherapy of solid tumors. Introduction of a multi-institutional research project. Strahlenther Onkol 2004;180:609-15.